Program
inebilizumab
Also written as “Inebilizumab”, “MEDI-551” and “MEDI-551 30 MG-IV”.
Its studies are mostly in Neuromyelitis Optica · Immunoglobulin G4-Related Disease · Myasthenia Gravis · Hepatitis, Autoimmune · Lupus Erythematosus, Systemic, led by 4 companies.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Amgen | 109 open or running | phase 4since Nov 17, 2023 | Nov 5, 2019 | Apr 13, 2027phase 2 · NCT05549258 |
| AstraZeneca | 70 open or running | phase 3since Jul 16, 2014 | Jul 23, 2009 | none ahead |
| Hansoh Pharmaceutical Group | 11 open or running | phase 4since Dec 15, 2023 | Dec 15, 2023 | none ahead |
| Tanabe Pharma | 11 open or running | phase 3since Jan 6, 2022 | Jan 6, 2022 | none ahead |
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). An open circle marks the day WHO proposed its name. Dates ahead are the sponsors’ estimates.
Before these, 5 studies since Jul 23, 2009.
- Oct 1, 2013Phase 1 study in Hematologic NeoplasmsAstraZeneca · NCT01957579 · 32 enrolled · Japan
- Jul 16, 2014Phase 3 study in Neuromyelitis OpticaAstraZeneca · NCT02200770 · 231 enrolled · United States, Australia, Bulgaria and more
- Jun 9, 2015Named inebilizumabINNProposed as its International Nonproprietary Name in WHO's List 113 · before, MEDI-551
- Nov 5, 2019Amgen’s first study: phase 2 study in Highly Sensitized Patients on Waiting List for Kidney TransplantationNew to AmgenAmgen · NCT04174677 · United States
- Aug 10, 2020Phase 3 study in Myasthenia GravisAmgen · NCT04524273 · 238 enrolled · United States, Argentina, Belarus and more
- Sep 1, 2020Phase 3 study in Immunoglobulin G4-Related DiseaseAmgen · NCT04540497 · 135 enrolled · United States, Argentina, Australia and more
- Jan 6, 2022Tanabe Pharma’s first study: phase 3 study in Scleroderma, SystemicNew to Tanabe PharmaTanabe Pharma · NCT05198557 · 80 enrolled · Japan
- Jul 22, 2022Phase 2 study in Neuromyelitis OpticaAmgen · NCT05549258 · 15 planned · United States, Argentina, Brazil and more
- Nov 17, 2023Phase 4 study in Neuromyelitis OpticaAmgen · NCT06180278 · 32 enrolled · United States, China, Czechia and more
- Dec 15, 2023Hansoh Pharmaceutical Group’s first study: phase 4 study in Neuromyelitis OpticaNew to Hansoh Pharmaceutical GroupHansoh Pharmaceutical Group · NCT06212245 · 33 planned · China
- Aug 22, 2024Phase 2 study in Lupus Erythematosus, SystemicAmgen · NCT06570798 · 220 planned · United States, Australia, Belgium and more
- May 16, 2025Phase 2 study in Myasthenia GravisAmgen · NCT06987539 · 15 planned · United States, Argentina, Brazil and more
- Oct 28, 2025Phase 2 study in Immunoglobulin G4-Related DiseaseAmgen · NCT07222553 · 15 planned · United States, Brazil, China and more
- May 14, 2026Phase 3 study in Hepatitis, AutoimmuneAmgen · NCT07598825 · 180 planned · United States, Belgium, Canada and more
- Sep 25, 2026Phase 3 study in Glomerulonephritis, MembranousAmgen · NCT07851220 · 159 planned · United States
Ahead
- Apr 13, 2027Primary completion: phase 2 study in Neuromyelitis OpticaAmgen · NCT05549258
- Jun 26, 2028Primary completion: phase 4 study in Neuromyelitis OpticaAmgen · NCT06180278
- Aug 6, 2028Primary completion: phase 2 study in Lupus Erythematosus, SystemicAmgen · NCT06570798
- Mar 13, 2030Primary completion: phase 2 study in Myasthenia GravisAmgen · NCT06987539
TargetBeta
“A humanized immunoglobulin IgG1 kappa monoclonal antibody directed against the B-cell-specific membrane protein CD-19 ”NCIt, by rule
“B-lymphocyte antigen CD19 binding agent”ChEMBL 37, by rule
Other programs on CD19
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| blinatumomabrule | Amgen | phase 4 | 29 |
| Autologous Bispecific BCMA/CD19-targeted CAR-T Cells GC012F | AstraZeneca | phase 3 | 12 |
| axicabtagene ciloleucelrule | Gilead Sciences | phase 3 | 10 |
| surovatamig | AstraZeneca | phase 3 | 10 |
| lisocabtagene maraleucelrule | Bristol-Myers Squibb | phase 3 | 10 |
| Anti-CD19/CD3 Bispecific Antibody MK-1045 | Merck | phase 3 | 8 |
| obexelimab | zenas-biopharma-usa-llc | phase 3 | 7 |
| Autologous Anti-CD19 CAR-T Cells CABA-201rule | cabaletta-bio | phase 3 | 6 |
| zolacabtagene autoleucel | Bristol-Myers Squibb | phase 3 | 6 |
| Autologous Anti-CD19/Anti-CD20 CAR-T Cells KITE-753rule | Gilead Sciences | phase 3 | 2 |
| rondecabtagene autoleucelrule | lyell-immunopharma-inc | phase 3 | 2 |
| rapcabtagene autoleucel | Novartis | phase 2 | 8 |
Studies
All 19 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Led by | Primary completion | Size |
|---|---|---|---|---|---|
| NCT07851220Glomerulonephritis, Membranous · United States | 3 | Recruiting | Amgen | Sep 27, 2031 | 159 |
| NCT07598825Hepatitis, Autoimmune · United States, Belgium, Canada and more | 3 | Recruiting | Amgen | Jul 30, 2031 | 180 |
| NCT07222553Immunoglobulin G4-Related Disease · United States, Brazil, China and more | 2 | Recruiting | Amgen | Jun 10, 2031 | 15 |
| NCT06987539Myasthenia Gravis · United States, Argentina, Brazil and more | 2 | Recruiting | Amgen | Mar 13, 2030 | 15 |
| NCT06570798Lupus Erythematosus, Systemic · United States, Australia, Belgium and more | 2 | Recruiting | Amgen | Aug 6, 2028 | 220 |
| NCT06212245Neuromyelitis Optica · China | 4 | Not yet recruiting | Hansoh Pharmaceutical Group | Dec 25, 2024 | 33 |
| NCT06180278Neuromyelitis Optica · United States, China, Czechia and more | 4 | Active, not recruiting | Amgen | Jun 26, 2028 | 32 |
| NCT05549258Neuromyelitis Optica · United States, Argentina, Brazil and more | 2 | Recruiting | Amgen | Apr 13, 2027 | 15 |
| NCT05198557Scleroderma, Systemic · Japan | 3 | Active, not recruiting | Tanabe Pharma | Jul 31, 2025 | 80 |
| NCT04540497Immunoglobulin G4-Related Disease · United States, Argentina, Australia and more | 3 | Active, not recruiting | Amgen | Apr 9, 2024 | 135 |
| NCT04524273Myasthenia Gravis · United States, Argentina, Belarus and more | 3 | Active, not recruiting | Amgen | May 28, 2024 | 238 |
| NCT04174677Highly Sensitized Patients on Waiting List for Kidney Transplantation · United States | 2 | Withdrawn | Amgen | Dec 2021 | 0 |
| NCT02200770Neuromyelitis Optica · United States, Australia, Bulgaria and more | 3 | Completed | AstraZeneca | Oct 26, 2018 | 231 |
| NCT01957579Hematologic Neoplasms · Japan | 1 | Completed | AstraZeneca | Sep 15, 2015 | 32 |
| NCT01585766Multiple Sclerosis · United States, Poland, Spain and more | 1 | Completed | AstraZeneca | Jan 2, 2015 | 56 |
| NCT01453205Lymphoma, Large B-Cell, Diffuse · United States, Canada, Czechia and more | 2 | Completed | AstraZeneca | Jul 11, 2016 | 187 |
| NCT01466153Leukemia, Lymphocytic, Chronic, B-Cell · United States, Belgium, Canada and more | 2 | Completed | AstraZeneca | Jan 8, 2016 | 183 |
| NCT00983619Neoplasms · United States, Belgium, Canada and more | 2 | Completed | AstraZeneca | Mar 21, 2019 | 136 |
| NCT00946699Scleroderma, Diffuse · United States, Canada, United Kingdom | 1 | Completed | AstraZeneca | Mar 2012 | 50 |
How it is read
Names in the registry
- “Inebilizumab”, 12 entries
- “MEDI-551”, 7 entries
- “inebilizumab”, 1 entry
- “MEDI-551 30 MG-IV”, 1 entry
- “MEDI-551 60 MG-SC”, 1 entry
Conditions, from the studies’ own filings
- Neuromyelitis Optica, 4 studies
- Immunoglobulin G4-Related Disease, 2 studies
- Myasthenia Gravis, 2 studies
- Hepatitis, Autoimmune, 1 study
- Lupus Erythematosus, Systemic, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.